Seres Therapeutics Inc (MCRB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Seres Therapeutics Inc (MCRB) has a cash flow conversion efficiency ratio of 0.050x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.21 Million) by net assets ($43.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Seres Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Seres Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Seres Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
Seres Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seres Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Best Agrolife Limited
NSE:BESTAGRO
|
N/A |
|
NN Inc
NASDAQ:NNBR
|
0.071x |
|
Alliance Aviation Services Ltd
AU:AQZ
|
-0.016x |
|
Joong Ang Enervis Co. Ltd
KQ:000440
|
-0.010x |
|
HNA Technology Co Ltd B
SHG:900938
|
-0.009x |
|
Synthaverse S.A.
WAR:SVE
|
0.072x |
|
MediciNova Inc
NASDAQ:MNOV
|
-0.039x |
|
Allcargo Terminals Ltd
NSE:ATL
|
0.638x |
Annual Cash Flow Conversion Efficiency for Seres Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Seres Therapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see MCRB company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.78 Million | $-148.61 Million | -10.781x | -512.09% |
| 2023-12-31 | $-44.86 Million | $-117.35 Million | 2.616x | +112.33% |
| 2022-12-31 | $10.78 Million | $-228.82 Million | -21.220x | -41825.29% |
| 2021-12-31 | $131.51 Million | $6.69 Million | 0.051x | +109.49% |
| 2020-12-31 | $174.75 Million | $-93.61 Million | -0.536x | -133.83% |
| 2019-12-31 | $-48.32 Million | $-76.52 Million | 1.583x | +21.04% |
| 2018-12-31 | $-48.05 Million | $-62.85 Million | 1.308x | +205.14% |
| 2017-12-31 | $60.70 Million | $-75.52 Million | -1.244x | -475.73% |
| 2016-12-31 | $132.63 Million | $43.92 Million | 0.331x | +266.53% |
| 2015-12-31 | $205.39 Million | $-40.84 Million | -0.199x | -151.30% |
| 2014-12-31 | $-26.72 Million | $-10.36 Million | 0.388x | +104.60% |
| 2013-12-31 | $631.00K | $-5.32 Million | -8.433x | -1733.56% |
| 2012-12-31 | $6.36 Million | $-2.92 Million | -0.460x | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outc… Read more